Individual risk assessment in MDS in the era of genomic medicine
Assessment of risk for patients with myelodysplastic syndromes has evolved from pure morphological bone marrow assessment to a series of validated prognostic scoring systems whose ‘risk’ assessment is of death (overall survival) or disease progression (AML transformation). The revised International Prognostic Scoring System (2012) improved the precision for prognosis but did not consider patient-specific factors such as comorbidity and performance status, which have a cle ar impact on outcome, particularly in lower-risk MDS.
Source: Seminars in Hematology - Category: Hematology Authors: Catherine Cargo, David Bowen Tags: 54/3 Therapies in MDS Source Type: research
More News: Hematology | Myelodysplastic Syndrome